Logo image of PROK

PROKIDNEY CORP (PROK) Stock Fundamental Analysis

NASDAQ:PROK - Nasdaq - KYG7S53R1049 - Common Stock - Currency: USD

1.5  -0.02 (-1.32%)

After market: 1.5 0 (0%)

Fundamental Rating

1

PROK gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. PROK has a bad profitability rating. Also its financial health evaluation is rather negative. PROK is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PROK has reported negative net income.
PROK had a negative operating cash flow in the past year.
PROK Yearly Net Income VS EBIT VS OCF VS FCFPROK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

With an excellent Return On Assets value of -9.61%, PROK belongs to the best of the industry, outperforming 87.21% of the companies in the same industry.
Industry RankSector Rank
ROA -9.61%
ROE N/A
ROIC N/A
ROA(3y)-55.38%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PROK Yearly ROA, ROE, ROICPROK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PROK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PROK Yearly Profit, Operating, Gross MarginsPROK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for PROK has been increased compared to 1 year ago.
The debt/assets ratio for PROK is higher compared to a year ago.
PROK Yearly Shares OutstandingPROK Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 50M 100M 150M 200M
PROK Yearly Total Debt VS Total AssetsPROK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -3.36, we must say that PROK is in the distress zone and has some risk of bankruptcy.
PROK has a Altman-Z score (-3.36) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.36
ROIC/WACCN/A
WACCN/A
PROK Yearly LT Debt VS Equity VS FCFPROK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 -200M -400M -600M -800M -1B

2.3 Liquidity

A Current Ratio of 17.09 indicates that PROK has no problem at all paying its short term obligations.
PROK has a Current ratio of 17.09. This is amongst the best in the industry. PROK outperforms 91.30% of its industry peers.
A Quick Ratio of 17.09 indicates that PROK has no problem at all paying its short term obligations.
The Quick ratio of PROK (17.09) is better than 91.30% of its industry peers.
Industry RankSector Rank
Current Ratio 17.09
Quick Ratio 17.09
PROK Yearly Current Assets VS Current LiabilitesPROK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

PROK shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.78%.
EPS 1Y (TTM)6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PROK will show a small growth in Earnings Per Share. The EPS will grow by 7.38% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-4.8%
EPS Next 2Y9.82%
EPS Next 3Y-10.84%
EPS Next 5Y7.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PROK Yearly Revenue VS EstimatesPROK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PROK Yearly EPS VS EstimatesPROK Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PROK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PROK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PROK Price Earnings VS Forward Price EarningsPROK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PROK Per share dataPROK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

PROK's earnings are expected to decrease with -10.84% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.82%
EPS Next 3Y-10.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PROK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROKIDNEY CORP

NASDAQ:PROK (2/21/2025, 8:00:01 PM)

After market: 1.5 0 (0%)

1.5

-0.02 (-1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)03-20 2025-03-20/amc
Inst Owners44.68%
Inst Owner Change-97.96%
Ins Owners3.31%
Ins Owner Change0.1%
Market Cap437.49M
Analysts81.54
Price Target5.1 (240%)
Short Float %12.82%
Short Ratio26.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.2%
Min EPS beat(2)5.99%
Max EPS beat(2)8.4%
EPS beat(4)4
Avg EPS beat(4)18.75%
Min EPS beat(4)5.99%
Max EPS beat(4)48.25%
EPS beat(8)7
Avg EPS beat(8)30.53%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.14%
EPS NQ rev (1m)-0.2%
EPS NQ rev (3m)7.95%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0
BVpS-3.36
TBVpS-3.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.61%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.38%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 111.32%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.09
Quick Ratio 17.09
Altman-Z -3.36
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)403.51%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y-4.8%
EPS Next 2Y9.82%
EPS Next 3Y-10.84%
EPS Next 5Y7.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.87%
EBIT Next 3Y-6.59%
EBIT Next 5YN/A
FCF growth 1Y-74.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.63%
OCF growth 3YN/A
OCF growth 5YN/A